Anixa Biosciences (ANIX) Cash from Operations (2010 - 2025)

Anixa Biosciences (ANIX) has reported Cash from Operations for 16 consecutive years, with -$1.3 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations fell 35.38% year-over-year to -$1.3 million; the trailing twelve-month figure through Oct 2025 stood at -$7.2 million (up 2.21% YoY), and the FY2025 full-year result was -$7.2 million, up 2.21% from the prior year.
• Cash from Operations improved to -$1.3 million in Q4 2025 per ANIX's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$807000.0 in Q2 2023 and bottomed at -$2.9 million in Q1 2025.
• Historically, Cash from Operations has averaged -$1.6 million across 5 years, with a median of -$1.5 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 85.67% in 2022, then surged 65.0% in 2023.
• Over 5 years, Cash from Operations stood at -$1.0 million in 2021, then slumped by 52.44% to -$1.6 million in 2022, then slipped by 23.6% to -$2.0 million in 2023, then soared by 52.92% to -$927000.0 in 2024, then plunged by 35.38% to -$1.3 million in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered -$1.3 million, -$1.5 million, and -$1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.